Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Type of study
Language
Document Type
Year range
1.
BMJ Case Rep ; 15(5)2022 May 11.
Article in English | MEDLINE | ID: covidwho-1840565

ABSTRACT

Since the start of vaccination against COVID-19 viral infection using adenovirus-based vector vaccine (eg, The Oxford-AstraZeneca vaccine, using the modified chimpanzee adenovirus ChAdOx1, and the Johnson & Johnson vaccine, using human adenovirus serotype 26), a rare, but potentially life-threatening complication called vaccine-induced thrombotic thrombocytopenia (VITT) was reported. As the number of cases increases every day, with the increase in the number of vaccinated people all over the world, this complication is a concern to the medical field. We report a case on the acute management of a patient who presented to us with life-threatening bilateral pulmonary embolism as a complication of VITT after the first dose of vaccination with Oxford-AstraZeneca vaccine against COVID-19.


Subject(s)
COVID-19 , Pulmonary Embolism , Thrombocytopenia , Thrombosis , Vaccines , COVID-19 Vaccines/adverse effects , ChAdOx1 nCoV-19 , Humans , Pulmonary Embolism/complications , Pulmonary Embolism/etiology , SARS-CoV-2 , Thrombocytopenia/chemically induced , Thrombosis/complications , Vaccination/adverse effects , Vaccines/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL